Along these lines, an ASO targeting GSK3-β, which can initiate β-TRCP-dependent degradation of NRF2, was shown to increase NRF2 levels, resulting in decreased oxidative stress and less severe learning and memory impairment in a SAMP8−/− AD mouse model (Farr et al., 2014). Here, NFE2L2 is linked to Alzheimer disease.